| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IDH3A |
| Uniprot No | P50213 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-366aa |
| 氨基酸序列 | MAGPAWISKVSRLLGAFHNPKQVTRGFTGGVQTVTLIPGDGIGPEISAAVMKIFDAAKAPIQWEERNVTAIQGPGGKWMIPSEAKESMDKNKMGLKGPLKTPIAAGHPSMNLLLRKTFDLYANVRPCVSIEGYKTPYTDVNIVTIRENTEGEYSGIEHVIVDGVVQSIKLITEGASKRIAEFAFEYARNNHRSNVTAVHKANIMRMSDGLFLQKCREVAESCKDIKFNEMYLDTVCLNMVQDPSQFDVLVMPNLYGDILSDLCAGLIGGLGVTPSGNIGANGVAIFESVHGTAPDIAGKDMANPTALLLSAVMMLRHMGLFDHAARIEAACFATIKDGKSLTKDLGGNAKCSDFTEEICRRVKDLD |
| 分子量 | 66 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人IDH3A蛋白的参考文献示例(注：部分内容为假设性举例，仅供参考)：
---
1. **文献名称**：*Expression and Characterization of Recombinant Human IDH3A in Escherichia coli*
**作者**：Kim, J. et al. (2020)
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组人IDH3A蛋白，优化了可溶性表达条件，验证了其与IDH3B亚基结合形成功能性异源二聚体的能力，并检测到依赖NAD+的酶活性，为IDH3复合体的功能研究提供了基础工具。
2. **文献名称**：*Structural Insights into IDH3A Mutations Associated with Metabolic Disorders*
**作者**：Chen, L. et al. (2021)
**摘要**：通过X射线晶体学解析了IDH3A蛋白的催化结构域，发现其活性位点关键氨基酸突变(如R140Q)会导致异柠檬酸脱氢酶活性显著降低，提示此类突变可能通过破坏三羧酸循环引发代谢性疾病。
3. **文献名称**：*IDH3A Deficiency Alters Cellular Metabolism and Promotes Tumorigenesis*
**作者**：Zhang, Y. et al. (2018)
**摘要**：构建了IDH3A敲低细胞模型，发现其缺失导致α-酮戊二酸水平下降和HIF-1α通路异常激活，促进肿瘤细胞增殖和糖酵解依赖，揭示了IDH3A在代谢重编程及癌症进展中的潜在作用。
4. **文献名称**：*High-throughput Screening of IDH3A Inhibitors for Anticancer Drug Development*
**作者**：Wang, T. et al. (2022)
**摘要**：基于重组IDH3A蛋白建立高通量筛选平台，鉴定了多种小分子抑制剂，其中化合物X3显著抑制胶质瘤细胞生长，为靶向IDH3A的抗癌药物研发提供新方向。
---
**注意**：上述文献为示例性质，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的文章。
Recombinant human IDH3A protein is a genetically engineered form of the isocitrate dehydrogenase 3 alpha subunit, a critical enzyme in the tricarboxylic acid (TCA) cycle. IDH3. a mitochondrial NAD+-dependent enzyme, catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), generating NADH for cellular energy metabolism. Unlike cancer-associated mutant IDH1/2 isoforms that produce the oncometabolite D-2-hydroxyglutarate (2-HG), wild-type IDH3 maintains normal metabolic flux. The IDH3 holoenzyme consists of α, β, and γ subunits, with IDH3A encoding the catalytic α subunit essential for enzyme activity. Recombinant IDH3A is typically expressed in E. coli or mammalian systems, purified via affinity tags, and used to study TCA cycle regulation, mitochondrial dysfunction, and metabolic diseases. Its applications include enzyme kinetics analysis, screening for metabolic modulators, and investigating mutations linked to degenerative conditions. Research on IDH3A also provides insights into pathological mechanisms involving α-KG homeostasis, such as retinitis pigmentosa (associated with IDH3B mutations) and potential cross-talk with IDH1/2 in cancers. This recombinant tool aids in distinguishing isoform-specific functions within the IDH family and developing targeted therapies for metabolic disorders.
×
